 CHARLOTTESVILLE, VA ACCESSWIRE July 6, 2020 Adial Pharmaceuticals, Inc. NASDAQ:ADIL:ADILW Adial, a clinical-stage biopharmaceutical company focused on the development of treatments for addiction, today announced that it has received approvals in Sweden and Estonia to commence the Companys landmark ONWARDTM pivotal Phase 3 clinical trial to investigate its lead drug candidate, AD04, as a therapeutic agent for the treatment of Alcohol Use Disorder AUD in persons with certain target genotypes related to the serotonin transporter and receptor genes. The Swedish Medical Products Agency and Swedish Ethical Review Authority have provided approval for ONWARDTM to commence in Sweden; and the Estonian State Agency of Medicines and Ethics Review Committee overseeing human trials granted approval to commence ONWARDTM in Estonia. 